Research type:
|
HTA Technology Assessment Report |
Title (lead author) etc:
|
Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation (Jones) 196 pages, Volume 13, number 35 |
DOI
|
10.3310/hta13350 |
View/print executive summary
View/print abstract
View full text in pdf format (1039 KB)
 This title is available on our CD-ROM of the journal.
 Order a CD-ROM - free of charge worldwide.
Go to our correspondence page to comment on this publication
|
Headline: |
Study found that both adefovir dipivoxil and pegylated interferon alpha are beneficial for patients with chronic hepatitis B in terms of suppressing viral load, reducing liver damage-associated biochemical activity, inducing HBeAg seroconversion, and reducing liver fibrosis and necroinflammation |
This report should be referenced as follows: |
Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P, et al. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. Health Technol Assess
2009;13(35).
|
Project ref: |
07/15/01 |
Original project title: |
Adefovir dipivoxil and pegylated interferon alfa for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation |
Chief Investigator: |
Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
|
Start Date: |
December 2007 |
Date of publication in HTA journal series |
July 2009
|
Cost: |
This project was commissioned by the HTA programme on a call-off contract basis. |
Project Protocol: |
Project protocol not available
|
Printed copies of this title despatched:
|
100 (Figures relate to the previous calendar month) |
URL of this page: |
http://www.hta.ac.uk/1718 |
News feeds